Logo image of CSLT

CASTLIGHT HEALTH INC-B (CSLT) Stock Fundamental Analysis

NYSE:CSLT - New York Stock Exchange, Inc. - Common Stock

2.05  +0.01 (+0.49%)

After market: 2.05 0 (0%)

Fundamental Rating

2

Overall CSLT gets a fundamental rating of 2 out of 10. We evaluated CSLT against 35 industry peers in the Health Care Technology industry. While CSLT seems to be doing ok healthwise, there are quite some concerns on its profitability. CSLT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CSLT was profitable.
CSLT Yearly Net Income VS EBIT VS OCF VS FCFCSLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -5.25%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSLT Yearly ROA, ROE, ROICCSLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 -20 -40 -60

1.3 Margins

Industry RankSector Rank
OM -6.17%
PM (TTM) -6.05%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CSLT Yearly Profit, Operating, Gross MarginsCSLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 50 -50 -100

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CSLT has more shares outstanding
There is no outstanding debt for CSLT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CSLT Yearly Shares OutstandingCSLT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 50M 100M 150M
CSLT Yearly Total Debt VS Total AssetsCSLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 2.04 indicates that CSLT is not a great score, but indicates only limited risk for bankruptcy at the moment.
CSLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.04
ROIC/WACCN/A
WACCN/A
CSLT Yearly LT Debt VS Equity VS FCFCSLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M -50M 100M 150M 200M

2.3 Liquidity

CSLT has a Current Ratio of 2.94. This indicates that CSLT is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 2.94 indicates that CSLT has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 2.94
Quick Ratio 2.94
CSLT Yearly Current Assets VS Current LiabilitesCSLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 266.67% over the past year.
Looking at the last year, CSLT shows a decrease in Revenue. The Revenue has decreased by -2.43% in the last year.
The Revenue has been growing by 14.27% on average over the past years. This is quite good.
EPS 1Y (TTM)266.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-2.43%
Revenue growth 3Y3.58%
Revenue growth 5Y14.27%
Sales Q2Q%-0.87%

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.
CSLT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.47% yearly.
EPS Next Y-100%
EPS Next 2Y-64.29%
EPS Next 3Y-36.59%
EPS Next 5Y0%
Revenue Next Year-1.74%
Revenue Next 2Y0.81%
Revenue Next 3Y2.09%
Revenue Next 5Y2.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CSLT Yearly Revenue VS EstimatesCSLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
CSLT Yearly EPS VS EstimatesCSLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 41.00, the valuation of CSLT can be described as expensive.
The average S&P500 Price/Earnings ratio is at 26.54. CSLT is valued rather expensively when compared to this.
With a Price/Forward Earnings ratio of 401.96, CSLT can be considered very expensive at the moment.
When comparing the Price/Forward Earnings ratio of CSLT to the average of the S&P500 Index (35.28), we can say CSLT is valued expensively.
Industry RankSector Rank
PE 41
Fwd PE 401.96
CSLT Price Earnings VS Forward Price EarningsCSLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300 400

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -118.87
CSLT Per share dataCSLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

CSLT's earnings are expected to decrease with -36.59% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.29%
EPS Next 3Y-36.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CSLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASTLIGHT HEALTH INC-B

NYSE:CSLT (2/16/2022, 8:16:48 PM)

After market: 2.05 0 (0%)

2.05

+0.01 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)N/A N/A
Earnings (Next)03-11 2022-03-11/amc
Inst Owners2.61%
Inst Owner Change0%
Ins Owners4.13%
Ins Owner Change0%
Market Cap332.37M
Analysts45.71
Price Target2.09 (1.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 41
Fwd PE 401.96
P/S 2.33
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB N/A
EV/EBITDA -118.87
EPS(TTM)0.05
EY2.44%
EPS(NY)0.01
Fwd EY0.25%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.88
BVpS0.78
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -6.17%
PM (TTM) -6.05%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.94
Quick Ratio 2.94
Altman-Z 2.04
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)266.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-100%
EPS Next 2Y-64.29%
EPS Next 3Y-36.59%
EPS Next 5Y0%
Revenue 1Y (TTM)-2.43%
Revenue growth 3Y3.58%
Revenue growth 5Y14.27%
Sales Q2Q%-0.87%
Revenue Next Year-1.74%
Revenue Next 2Y0.81%
Revenue Next 3Y2.09%
Revenue Next 5Y2.47%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A